Beyond Diabetes and Weight Management

GLP-1-Based Medication Indications With Medicare Part D and Michigan Medicaid Coverage

This tool outlines the required testing and diagnostic criteria for alternative indications for Medicare Part D coverage and Medicaid coverage for GLP-1-based medications.

Indication	Required Testing / Diagnostic Criteria		Covered Medication
Cardiovascular Risk Reduction	Prior MI	Documentation of hospitalization, elevated troponin, ECG findings, or cardiac catheterization/PCI.	Semaglutide **subcutaneous and oral** under the brand name Wegovy
	Stroke	Documentation of ischemic or hemorrhagic stroke, supported by neuroimaging.	
	Symptomatic PAD	Resting ABI <0.85 with claudication; prior peripheral revascularization; or amputation due to atherosclerotic disease.	
Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)	MASH with stage F2 to F3 fibrosis, include date or documentation of biopsy or accepted noninvasive tests: • FibroScan (VCTE) showing F2/F3 fibrosis. • Documentation must confirm noncirrhotic status (no F4).		Semaglutide **subcutaneous** under the brand name Wegovy
Sleep Apnea (Moderate - Severe)	• Include date of sleep study and documentation of AHI/REI of 15 or more events per hour on polysomnography (PSG) or a home sleep apnea test (HSAT). • Moderate: AHI/REI 15 to 29. • Severe: AHI/REI 30 or higher. • Plus BMI of 30 kg/m2 or higher.		Tirzepatide under the brand name Zepbound

Michigan Medicaid
Effective January 1, 2026, Michigan restricted GLP-1-based med coverage for weight management alone to beneficiaries with morbid obesity (BMI 40 or higher) who have documented failure of other interventions, used as a measure to avert bariatric surgery. That restriction applies only to the weight-management pathway. Per MDHHS, coverage for the three indications above did not change.

Michigan Medicaid prior authorization requirements: michmed.org/9Zmyr (PA requirements on Page 33)

Medicare GLP-1-based medications Bridge Program
From July 1, 2026 through December 31, 2027, a separate CMS demonstration provides an additional coverage pathway for weight management. It does not replace the coverage above. **If a patient meets the criteria above, the prescription must be submitted through standard Part D, not the Bridge program.**

Pivotal trials
1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.
2. Sanyal AJ, Newsome PN, Kliers I, et al; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089-2099.
3. Malhotra A, Grunstein RR, Fietze I, et al; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205.

Regulatory and payer sources
1. Michigan Department of Health and Human Services. Numbered Letter L 25-73, Update of Pharmacy Drug Coverage for Treatment of Obesity, December 8, 2025. michigan.gov/mdhhs.